The company is focused on expanding distribution, raising commercial awareness, and pursuing reimbursements, with products delivering impressive results and high patient satisfaction positioned to fill a market void. The company targets biofilm prevention, pain therapy, wound healing, and at-home administration without medical professional assistance.
Cyborg Score Rationale
NanoVibronix operates in the competitive medical device sector with proprietary acoustic technology and FDA/CE Mark clearances for key products. However, as a micro-cap with limited scale, the company faces challenges in market penetration, reimbursement, and cash flow, requiring successful global commercialization to validate long-term viability.
Top Insights
Products leverage patented low-intensity surface acoustic wave technology for disruption of biofilms, bacterial colonization, and pain relief applications
Direct-to-patient and distributor sales model across US, Europe, Australia, Israel, New Zealand, and international markets
Company regained full NASDAQ compliance in November 2023 after meeting minimum stockholders' equity requirement
Portfolio expansion underway including pediatric feeding tube guidance system through ENvue Medical Holdings division
Named Competitors
Therapeutic Ultrasound Devices — Diversified medical technology including orthopedic and therapeutic devices
Pain Management Solutions — Orthopedic and wound care products (Johnson & Johnson subsidiary)
Wound Care and Biofilm Solutions — Advanced wound management and surgical solutions
Recent Developments
(July 2025) Appointed Rita Silberberg as Executive Vice President of Finance, Chief Accountant